We hope to be cured when we stay in hospital. But too often, we acquire new infections there. Such 'healthcare-associated infections' (HAI) are a growing problem worldwide, taking up an estimated 6% ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

Despite rigorous cleaning, dangerous bacteria are lurking in hospital sink drains leading to a rise in ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

As antibiotic development declines and resistance rises, healthcare-associated infections (HAIs) remain a constant threat to patient welfare. Augmented by multiple-drug resistance, HAIs pose an ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

In the short-term, with therapeutic options dwindling, it is essential that the last remaining antimicrobials be safeguarded through rational selection and improved infection control. The ...